Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II neoadjuvant retlirafusp alfa plus SOX in TGFBR2-wild-type locally advanced gastric/GEJ adenocarcinoma
ChiCTR2600135037Phase 2Not yet recruiting
- Sponsor
- Xijing Hospital
- Start
- Nov 2026
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of retlirafusp alfa, oxaliplatin and tegafur in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma, sponsored by Xijing Hospital. Primary endpoint: Pathological complete response rate. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
retlirafusp alfaoxaliplatintegafur
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on ChiCTR2600135037.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600135037.